<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792934</url>
  </required_header>
  <id_info>
    <org_study_id>2012-073</org_study_id>
    <nct_id>NCT01792934</nct_id>
  </id_info>
  <brief_title>Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases</brief_title>
  <acronym>ORCHESTRA</acronym>
  <official_title>A Randomized Multicenter Clinical Trial for Patient With Multi-organ, Colorectal Cancer Metastases Comparing the Combination of Chemotherapy and Maximal Tumor Debulking Versus Chemotherapy Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare overall survival rates of colorectal cancer patients&#xD;
      with multi-organ metastases with an indication for first line systemic treatment randomized&#xD;
      for treatment with combination chemotherapy or treatment with combination chemotherapy and&#xD;
      additional maximal tumor debulking including surgical tumor resection, RFA, (DEBIRI-)TACE and&#xD;
      SBRT, depending on best clinical judgement according to a standardized treatment algorithm.&#xD;
      Our hypothesis is that maximal tumor debulking in addition to systemic treatment with&#xD;
      chemotherapy and biologicals will provide an improvement in progression free and overall&#xD;
      survival in this patient group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from date of study inclusion until the date of death or until the end of follow up, assessed up to 10 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival rates</measure>
    <time_frame>date of study inclusion to the first event defined as local recurrence or progression, distant recurrence or death from any cause assessed up to 10 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>assessed every 3 months, after a follow up of 3 years assessed every 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and efficacy of the additional local treatment measured by number of serious adverse events.</measure>
    <time_frame>assessed after inclusion of 25, 50 and 100 patients, after 30% of the patients are included in the study for 12 months and after the end of follow up, assessed up to 10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">478</enrollment>
  <condition>Multi-organ Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>XELOX or FOLFOX regimen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>XELOX or FOLFOX regimen and maximal tumor debulking including Surgery, radiofrequency ablation (RFA), transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI)-TACE) or stereotactic body radiation therapy (SBRT).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XELOX regimen according to standard procedures</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen according to standard procedures</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>radiofrequency ablation (RFA)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy (SBRT)</intervention_name>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>may be added to both regimens according to standard procedures</description>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>tumor biopsy</intervention_name>
    <description>at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy</description>
    <arm_group_label>XELOX or FOLFOX regimen</arm_group_label>
    <arm_group_label>XELOX or FOLFOX regimen and maximal tumor debulking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological documentation of cancer is required.&#xD;
&#xD;
          -  Indication for first line palliative systemic treatment for metastatic colorectal&#xD;
             cancer (mCRC).&#xD;
&#xD;
          -  Patients with CRC metastases in (the primary tumor is excluded as metastatic site)&#xD;
&#xD;
               -  ≥ 2 different organs if at least &gt;1 extra-hepatic metastases or&#xD;
&#xD;
               -  ≥ 2 different organs including &gt;5 hepatic metastases not located to one lobe or&#xD;
&#xD;
               -  ≥ 2 different organs including either a positive para-aortal lymph nodes or&#xD;
                  celiac lymph nodes or adrenal metastases or pleural carcinomatosis or peritoneal&#xD;
                  carcinomatosis&#xD;
&#xD;
          -  Feasible radical tumor debulking. Incomplete tumor debulking is allowed only if at&#xD;
             least 80% of metastases can be treated.&#xD;
&#xD;
          -  To meet the inclusion criteria a cytological analysis should be performed in case of&#xD;
             any uncertainty about the presence of a lesion e.g. a false positive or false negative&#xD;
             result on imaging.&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  WHO performance status 0 - 1.&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             requirements to be conducted within 7 days prior to screening:&#xD;
&#xD;
               -  Hemoglobin ≥ 5.6 mmol/L;&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mm3;&#xD;
&#xD;
               -  Platelet count ≥ 100*109/l;&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 times the upper limit of normal;&#xD;
&#xD;
               -  ALT and AST ≤ 2.5 x upper limit of normal (≤ 5 x upper limit of normal for&#xD;
                  subjects with liver involvement of their cancer);&#xD;
&#xD;
               -  Albumin &gt; 30 g/l;&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x upper limit of normal or a MDRD ≥ 50 ml/min;&#xD;
&#xD;
               -  Prothrombin time or INR &lt; 1.5 x ULN, unless coumarin derivates are used. Due to&#xD;
                  interactions with capecitabine, all patients using coumarin derivates will be&#xD;
                  treated with LMWH instead.&#xD;
&#xD;
               -  Activated partial thromboplastin time &lt; 1.25 x ULN (therapeutic anticoagulation&#xD;
                  therapy is allowed if this treatment can be interrupted as judged by the treating&#xD;
                  physician).&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior (neo-)adjuvant chemotherapy for &lt; 6 months after last treatment and first&#xD;
             detection of extra-hepatic metastases, except for neoadjuvant capecitabine in the&#xD;
             context of chemoradiation for rectal carcinoma.&#xD;
&#xD;
          -  Candidates for HIPEC.&#xD;
&#xD;
          -  Patients with liver metastases only&#xD;
&#xD;
          -  Evidence of brain metastases.&#xD;
&#xD;
          -  History of other prior malignancy except for adequately treated basal cell or squamous&#xD;
             cell skin cancer or in situ cervical cancer. Patients with other malignancies are&#xD;
             eligible if they have remained disease free for at least 5 years.- History of cardiac&#xD;
             disease:&#xD;
&#xD;
               -  Congestive heart failure &gt;NYHA class 2;&#xD;
&#xD;
               -  Active Coronary Artery Disease (defined as myocardial infarction within 6 months&#xD;
                  prior to screening);&#xD;
&#xD;
               -  Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin&#xD;
                  are permitted).&#xD;
&#xD;
          -  Uncontrolled hypertension. Blood pressure must be ≤160/95 mm Hg at the time of&#xD;
             screening on a stable antihypertensive regimen. Blood pressure must be stable on at&#xD;
             least 3 separate measurements on at least 2 separate days.&#xD;
&#xD;
          -  Uncontrolled infections (&gt; grade 2 NCI-CTC version 4.0).&#xD;
&#xD;
          -  Pregnant or breast-feeding women. Women of childbearing potential must have a negative&#xD;
             pregnancy test performed within 7 days of the start of treatment. Both men and women&#xD;
             enrolled in this trial must agree to use adequate barrier birth control measures&#xD;
             (e.g., cervical cap, condom, and diaphragm) or intrauterine device during the course&#xD;
             of the trial. Oral birth control methods alone will not be considered adequate on this&#xD;
             study, because of the potential pharmacokinetic interaction between study drug and&#xD;
             oral contraceptives. Concomitant use of oral and barrier contraceptives is advised.&#xD;
&#xD;
          -  Concurrent anticancer chemotherapy, immunotherapy or investigational drug therapy&#xD;
             during the study or within 4 weeks of the start of study drug.&#xD;
&#xD;
          -  Concomitant use of dexamethasone, anticonvulsants and anti-arrhythmic drugs other than&#xD;
             digoxin or beta blockers.&#xD;
&#xD;
          -  Severe allergy for contrast media not controlled with premedication.&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results.&#xD;
&#xD;
          -  Any condition that is unstable or could jeopardize the safety of the subject and their&#xD;
             compliance in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H.M.W. Verheul, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>H.M.W. Verheul, MD PhD</last_name>
    <email>henk.verheul@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lotte Bakkerus, MD</last_name>
    <phone>0031 (0)6 21000287</phone>
    <email>lotte.bakkerus@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Noordwest Ziekenhuis Groep</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MP Hendriks, Dr</last_name>
    </contact>
    <investigator>
      <last_name>MP Hendriks, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente</name>
      <address>
        <city>Almelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R Hoekstra, R</last_name>
    </contact>
    <investigator>
      <last_name>R Hoekstra, R</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander Medisch Centrum</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.M. Dodewaard</last_name>
    </contact>
    <investigator>
      <last_name>J.M. Dodewaard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amstelveen Ziekenhuis</name>
      <address>
        <city>Amstelveen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>AA van Zweeden, Drs</last_name>
    </contact>
    <investigator>
      <last_name>AA van Zweeden, Drs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <zip>NL-1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>K.S. Versteeg, MD, PhD</last_name>
      <phone>0031-20-4444321</phone>
      <email>k.versteeg@amsterdamumc.nl</email>
    </contact>
    <investigator>
      <last_name>K.S. Versteeg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academisch Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PJ Tanis, Dr</last_name>
    </contact>
    <investigator>
      <last_name>PJ Tanis, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C.M.I. Grootscholten</last_name>
    </contact>
    <investigator>
      <last_name>C.M.I. Grootscholten</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gelre</name>
      <address>
        <city>Apeldoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H. Meulenbeld</last_name>
    </contact>
    <investigator>
      <last_name>H. Meulenbeld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>O. Loosveld, Dr</last_name>
    </contact>
    <investigator>
      <last_name>O. Loosveld, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jeroen Bosch Ziekenhuis</name>
      <address>
        <city>Den Bosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JFM Pruijt, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JFM Pruijt, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Haaglanden</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HH Helgason, Dr</last_name>
    </contact>
    <investigator>
      <last_name>HH Helgason, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deventer Ziekenhuis</name>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H Torrenga, Dr</last_name>
    </contact>
    <investigator>
      <last_name>H Torrenga, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albert Schweizer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Trajkovic, MD</last_name>
    </contact>
    <investigator>
      <last_name>M Trajkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>G Vreugdenhil, Dr</last_name>
    </contact>
    <investigator>
      <last_name>G Vreugdenhil, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L.J.M. Mekenkamp</last_name>
    </contact>
    <investigator>
      <last_name>L.J.M. Mekenkamp</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dijklander</name>
      <address>
        <city>Hoorn</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Vleugel</last_name>
    </contact>
    <investigator>
      <last_name>M. Vleugel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Polee, Dr</last_name>
    </contact>
    <investigator>
      <last_name>M Polee, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sint Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M Los, Dr</last_name>
    </contact>
    <investigator>
      <last_name>M Los, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.M.W. Verheul, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>HMW Verheul, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bravis ziekenhuis</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F. Terheggen, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>F. Terheggen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>NL-3075 EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>C. Verhoef, MD PhD</last_name>
      <phone>0031 (0)10 7040704</phone>
      <email>c.verhoef@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>C. Verhoef, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D. Mathijssen, Dr</last_name>
    </contact>
    <investigator>
      <last_name>D. Mathijssen, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IJsselland ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vermaas</last_name>
    </contact>
    <investigator>
      <last_name>Vermaas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>B.C.M. Haberkorn, Dr</last_name>
    </contact>
    <investigator>
      <last_name>B.C.M. Haberkorn, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Elisabeth Tweesteden Ziekenhuis</name>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>L Beerepoot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>L Beerepoot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Admiraal de Ruyter Hospital</name>
      <address>
        <city>Vlissingen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>van Halteren</last_name>
    </contact>
    <investigator>
      <last_name>van Halteren</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zaans Medisch Centrum</name>
      <address>
        <city>Zaandam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S. Bakker</last_name>
    </contact>
    <investigator>
      <last_name>S. Bakker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JWB de Groot, Dr</last_name>
    </contact>
    <investigator>
      <last_name>JWB de Groot, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. Bridgewater</last_name>
    </contact>
    <investigator>
      <last_name>J. Bridgewater</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.N. Primrose</last_name>
    </contact>
    <investigator>
      <last_name>J.N. Primrose</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>February 13, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>June 20, 2021</last_update_submitted>
  <last_update_submitted_qc>June 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Debulking, cytoreduction, RFA, SABR, palliative chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

